Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company's common stock. About Phio Pharmaceuticals Corp. Phio...
2024-07-05 8:00 AM EDT
Phio Pharmaceuticals Announces Reverse Stock Split
Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-9. The reverse stock split will become effective at 12:01 a.m....
2024-07-02 11:45 AM EDT
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Marlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, has been granted a skin care patent in South Korea. The patent, METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING MMP1, covers the INTASYL RXI-185 compound that treats aging and skin disorders,...
2024-06-18 7:30 AM EDT
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
Marlborough, Massachusetts--(Newsfile Corp. - May 28, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that a Safety Monitoring Committee (SMC) reviewed safety data from the first dose cohort treated in the Phase 1b clinical trial with Phio's lead compound PH-762. Based on these findings, the SMC recommended...
2024-05-28 7:30 AM EDT
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead product candidate, PH-762, an INTASYL compound, at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, Illinois. Phio is...
2024-05-23 5:00 PM EDT